• 5 min read
• Published on 25 July 2025
Listen to article
6:32Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Let's be frank. In the world of investing, one company's rather public face-plant can be another's golden opportunity. And so it was when the pharmaceutical behemoth Organon announced it was ditching its experimental endometriosis drug. After the treatment, known as OG-6219, failed to impress in Phase 2 trials, the company packed its bags and walked away. For Organon, it was a costly write-off. For a handful of smaller biotech firms, it was as if the school bully had suddenly moved to another town, leaving the entire playground open.
I find these moments fascinating. It’s a stark reminder that for all the talk of synergy and collaboration, the market is often a zero-sum game. Organon’s exit from this particular race doesn’t just remove a competitor, it completely redraws the map.
To understand why this is such a big deal, you have to appreciate the sheer scale of the problem Organon was trying to solve. Endometriosis is a truly dreadful condition that affects roughly one in ten women. That’s about 190 million people worldwide dealing with chronic pain and a distinct lack of decent treatment options. Most existing therapies are hormonal sledgehammers with a litany of side effects, or surgery that often provides only temporary relief.
Organon’s drug was meant to be the clever, non-hormonal solution. Its failure leaves a gaping hole in a market that analysts believe is worth billions. Suddenly, the smaller, nimbler companies that were struggling for air in Organon’s shadow have a clear shot at the prize. The competitive pressure has eased, and their own development programmes look infinitely more attractive to potential partners and, of course, to investors.
So, who are these companies stepping into the limelight? You have firms like Femasys, a company that has staked its entire reputation on women’s health. With a major rival gone, its portfolio suddenly seems a lot more valuable. It’s what you might call a pure-play, a specialist in a field that is now conspicuously less crowded.
Then you have a different sort of contender, like TherapeuticsMD. This company isn't just working on pipeline drugs, it already has approved products on the market. Organon’s failure makes existing, proven treatments look that much more reliable. They have the sales teams and the doctor relationships already in place, which is a massive advantage when others are still navigating the treacherous waters of clinical trials. To me, they look like the established professional in a room full of ambitious graduates.
And you can’t ignore the interesting outsiders, like FibroGen. While not a direct endometriosis player, its work on related conditions like uterine fibroids gives it a unique perspective. Its expertise in fibrotic diseases could be cleverly repurposed now that the field is more open. Sometimes, the most interesting breakthroughs come from these adjacent fields of study.
Now, before we all get carried away, a word of caution is in order. The very event that created this opportunity is also a warning. Organon is a massive, well-funded company with some of the best minds in the business, and even they couldn't make it work. Biotech investing is not for the faint of heart. It is a high-stakes game where failure is not just possible, but common.
The path from a promising molecule to an approved, money-making drug is littered with pitfalls. Any of these smaller companies could stumble at the exact same hurdles that tripped up Organon. That is the fundamental risk you accept when you venture into this sector. But for those with a stomach for it, moments like these are where real opportunities might be found. The key is to understand the new landscape. For those of us tracking these shifts, it's about watching how these firms navigate the path now cleared for them. It’s precisely this kind of dynamic that informs thematic investing, grouping together companies like those in the {{ $json.output.basketName }} that are positioned to address these significant market gaps.
View the full Basket:New Opportunities in Endometriosis Treatment
View the full Basket:New Opportunities in Endometriosis Treatment
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article